199 related articles for article (PubMed ID: 32450274)
1. Comparison of Three Sequencing Panels Used for the Assessment of Tumor Mutational Burden in NSCLC Reveals Low Comparability.
Heeke S; Benzaquen J; Hofman V; Long-Mira E; Lespinet V; Bordone O; Marquette CH; Delingette H; Ilié M; Hofman P
J Thorac Oncol; 2020 Sep; 15(9):1535-1540. PubMed ID: 32450274
[TBL] [Abstract][Full Text] [Related]
2. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
3. Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB
Ramos-Paradas J; Hernández-Prieto S; Lora D; Sanchez E; Rosado A; Caniego-Casas T; Carrizo N; Enguita AB; Muñoz-Jimenez MT; Rodriguez B; Perez-Gonzalez U; Gómez-Sánchez D; Ferrer I; Ponce Aix S; Nuñez Buiza Á; Garrido P; Palacios J; Lopez-Rios F; Garrido-Martin EM; Paz-Ares L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963008
[TBL] [Abstract][Full Text] [Related]
4. Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative.
Esposito Abate R; Pasquale R; Sacco A; Simeon V; Maiello MR; Frezzetti D; Chiodini P; Normanno N
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309725
[TBL] [Abstract][Full Text] [Related]
5. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
Endris V; Buchhalter I; Allgäuer M; Rempel E; Lier A; Volckmar AL; Kirchner M; von Winterfeld M; Leichsenring J; Neumann O; Penzel R; Weichert W; Glimm H; Fröhling S; Winter H; Herth F; Thomas M; Schirmacher P; Budczies J; Stenzinger A
Int J Cancer; 2019 May; 144(9):2303-2312. PubMed ID: 30446996
[TBL] [Abstract][Full Text] [Related]
6. In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients.
Heeke S; Benzaquen J; Long-Mira E; Audelan B; Lespinet V; Bordone O; Lalvée S; Zahaf K; Poudenx M; Humbert O; Montaudié H; Dugourd PM; Chassang M; Passeron T; Delingette H; Marquette CH; Hofman V; Stenzinger A; Ilié M; Hofman P
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31470674
[TBL] [Abstract][Full Text] [Related]
7. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
8. HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.
Cuppens K; Baas P; Geerdens E; Cruys B; Froyen G; Decoster L; Thomeer M; Maes B
Lung Cancer; 2022 Aug; 170():1-10. PubMed ID: 35689896
[TBL] [Abstract][Full Text] [Related]
9. Tumor Mutational Burden by Whole-Genome Sequencing in Resected NSCLC of Never Smokers.
Ruel LJ; Li Z; Gaudreault N; Henry C; Saavedra Armero V; Boudreau DK; Zhang T; Landi MT; Labbé C; Couture C; Desmeules P; Joubert P; Bossé Y
Cancer Epidemiol Biomarkers Prev; 2022 Dec; 31(12):2219-2227. PubMed ID: 36126278
[TBL] [Abstract][Full Text] [Related]
10. Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
Chen X; Fang L; Zhu Y; Bao Z; Wang Q; Liu R; Sun W; Du H; Lin J; Yu B; Chen S; Zhou J; Zhou J
Cancer Immunol Immunother; 2021 Dec; 70(12):3513-3524. PubMed ID: 33899131
[TBL] [Abstract][Full Text] [Related]
11. Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'.
Wu HX; Wang ZX; Zhao Q; Wang F; Xu RH
J Immunother Cancer; 2019 Aug; 7(1):206. PubMed ID: 31387639
[TBL] [Abstract][Full Text] [Related]
12. Utility of Tumor Mutational Burden as a Biomarker for Response to Immune Checkpoint Inhibition in the VA Population.
Scobie MR; Zhou KI; Ahmed S; Kelley MJ
JCO Precis Oncol; 2023 Sep; 7():e2300176. PubMed ID: 38039430
[TBL] [Abstract][Full Text] [Related]
13. A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay.
Chaudhary R; Quagliata L; Martin JP; Alborelli I; Cyanam D; Mittal V; Tom W; Au-Young J; Sadis S; Hyland F
Transl Lung Cancer Res; 2018 Dec; 7(6):616-630. PubMed ID: 30505706
[TBL] [Abstract][Full Text] [Related]
14. Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort.
Bevins N; Sun S; Gaieb Z; Thorson JA; Murray SS
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217764
[TBL] [Abstract][Full Text] [Related]
15. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
16. Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer.
Park S; Lee C; Ku BM; Kim M; Park WY; Kim NKD; Ahn MJ
BMB Rep; 2021 Jul; 54(7):386-391. PubMed ID: 34154699
[TBL] [Abstract][Full Text] [Related]
17. Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing.
Wang HY; Deng L; Li YQ; Zhang X; Long YK; Zhang X; Feng YF; He Y; Tang T; Yang XH; Wang F
Cancer Res Treat; 2021 Oct; 53(4):973-982. PubMed ID: 33677848
[TBL] [Abstract][Full Text] [Related]
18. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
[TBL] [Abstract][Full Text] [Related]
19. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
Sabari JK; Leonardi GC; Shu CA; Umeton R; Montecalvo J; Ni A; Chen R; Dienstag J; Mrad C; Bergagnini I; Lai WV; Offin M; Arbour KC; Plodkowski AJ; Halpenny DF; Paik PK; Li BT; Riely GJ; Kris MG; Rudin CM; Sholl LM; Nishino M; Hellmann MD; Rekhtman N; Awad MM; Drilon A
Ann Oncol; 2018 Oct; 29(10):2085-2091. PubMed ID: 30165371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
